Cboe US - Delayed Quote USD

VanEck Morningstar Wide Moat ETF (MOAT)

85.47 -0.28 (-0.33%)
At close: April 25 at 4:00 PM EDT
85.99 +0.52 (+0.61%)
After hours: April 25 at 7:48 PM EDT
Loading Chart for MOAT
DELL
  • Previous Close 85.75
  • Open 85.52
  • Bid --
  • Ask --
  • Day's Range 84.82 - 85.75
  • 52 Week Range 70.56 - 90.14
  • Volume 886,028
  • Avg. Volume 931,490
  • Net Assets 15.13B
  • NAV 85.44
  • PE Ratio (TTM) 27.21
  • Yield 0.81%
  • YTD Daily Total Return 0.71%
  • Beta (5Y Monthly) 1.01
  • Expense Ratio (net) 0.47%

The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index is comprised of securities issued by companies that Morningstar, Inc. ("Morningstar") determines to have sustainable competitive advantages based on a proprietary methodology that considers quantitative and qualitative factors ("wide moat companies").

VanEck

Fund Family

Large Blend

Fund Category

15.13B

Net Assets

2012-04-24

Inception Date

Performance Overview: MOAT

Trailing returns as of 4/25/2024. Category is Large Blend.

YTD Return

MOAT
0.71%
Category
9.95%
 

1-Year Return

MOAT
19.46%
Category
27.24%
 

3-Year Return

MOAT
6.97%
Category
9.88%
 

People Also Watch

Holdings: MOAT

Top 10 Holdings (26.29% of Total Assets)

SymbolCompany% Assets
CTVA
Corteva, Inc. 2.73%
GOOGL
Alphabet Inc. 2.68%
ALLE
Allegion plc 2.67%
VEEV
Veeva Systems Inc. 2.66%
TER
Teradyne, Inc. 2.61%
RTX
RTX Corporation 2.60%
IFF
International Flavors & Fragrances Inc. 2.60%
TRU
TransUnion 2.59%
EL
The Estée Lauder Companies Inc. 2.57%
SCHW
The Charles Schwab Corporation 2.57%

Sector Weightings

SectorMOAT
Healthcare   21.74%
Industrials   18.28%
Technology   14.76%
Real Estate   0.00%
Utilities   0.00%
Energy   0.00%

Recent News: MOAT

Top ETF trends heading into 2024

Top ETF trends heading into 2024

Research Reports: MOAT

  • Analyst Report: Biogen Inc.

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

    Rating
    Price Target
     
  • Analyst Report: Enphase Energy, Inc.

    Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.

    Rating
    Price Target
     
  • Analyst Report: United Airlines Holdings Inc

    Based in Chicago, United Airlines Holdings is a global airline that transports passengers and freight through both mainline and regional operations. With a market cap of about $13.6 billion, United Airlines is generally regarded as a large-cap value stock.

    Rating
    Price Target
     
  • MPW: What does Argus have to say about MPW?

    MEDICAL PROPERTIES TRUST INC has an Investment Rating of SELL; a target price of $3.000000; an Industry Subrating of Low; a Management Subrating of High; a Safety Subrating of Low; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     

Related Tickers